BioStem Technologies, Inc.: Matuszewski Jason discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Jason Matuszewski disclosed a stake exceeding 5% in BioStem Technologies, Inc. via a Schedule 13G filing with the SEC (accession 0001213900-26-118035). The filing signals that an investor has crossed the threshold requiring public disclosure under SEC beneficial ownership rules. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings to gauge whether the position is passive or activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
BioStem Technologies, Inc., Matuszewski Jason